Evaluation of Heart Rate and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis: The HARLEY Study

The primary objective of the study titled "HeArt Rate and quality of Life in transthyrEtin cardiac amYloidosis (HARLEY)" is to evaluate the impact of **transthyretin cardiac amyloidosis** on heart rate and quality of life. This is clinically relevant as transthyretin cardiac amyloidosis is a progressive condition that can significantly affect cardiac function and patient well-being. Understanding its effects on heart rate and quality of life can inform treatment strategies and improve patient management.

The clinical trial involves participants diagnosed with **transthyretin cardiac amyloidosis**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been disclosed. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the impact of interventions on **transthyretin cardiac amyloidosis**, a rare disease. The study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is set to commence recruitment on January 13, 2025, and is expected to conclude by January 31, 2027, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. This initial visit will determine eligibility based on predefined criteria. Following successful inclusion, participants will attend regular follow-up visits, which are scheduled to monitor health status, adherence to the protocol, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the intervention.

The expected duration of participant involvement will span the entire trial period, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. These measures ensure the safety and integrity of the trial while maintaining the scientific validity of the results.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is scheduled to commence recruitment on January 13, 2025, with an estimated completion date of January 31, 2027. The trial is categorized under phase 6, indicating an advanced stage of clinical research. Efficacy assessments will be conducted throughout the trial to evaluate the therapeutic impact of the investigational product. The specific parameters or endpoints for efficacy evaluation have not been detailed in the available data. The trial will adhere to a structured schedule for measuring and collecting efficacy data, although the precise methods and instruments for these assessments are not specified. The trial's design and execution will follow rigorous scientific standards to ensure the reliability and validity of the efficacy outcomes.